{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:25:55Z","timestamp":1739424355779,"version":"3.37.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ejphar.2009.10.024","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T08:15:40Z","timestamp":1255767340000},"page":"S10-S16","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Ten years of infliximab: Its role in dermatology"],"prefix":"10.1016","volume":"623","author":[{"given":"Ulrich","family":"Mrowietz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2009.10.024_bib1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2009.10.024_bib2","first-page":"107","article-title":"Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system","volume":"14","author":"Augustin","year":"2004","journal-title":"Eur. J. Dermatol"},{"key":"10.1016\/j.ejphar.2009.10.024_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.024_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ejphar.2009.10.024_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2009.10.024_bib7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.024_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1185\/030079904X15192","article-title":"The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US","volume":"20","author":"Crown","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2009.10.024_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo- controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2009.10.024_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib13","first-page":"1116","article-title":"Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis","volume":"159","author":"Gerdes","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-X","article-title":"Disease concomitance in psoriasis","volume":"32","author":"Henseler","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology quality of life index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib17","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1365-2133.2005.06576.x","article-title":"Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life","volume":"152","author":"Katugampola","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2009.10.024_bib18","doi-asserted-by":"crossref","first-page":"ii34","DOI":"10.1136\/ard.62.suppl_2.ii34","article-title":"Advances in targeted therapy: safety of biological agents","volume":"62","author":"Keystone","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2009.10.024_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.ejphar.2009.10.024_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.024_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14656566.7.2.157","article-title":"Cost-effectiveness of moderate-to-severe psoriasis treatment","volume":"7","author":"Miller","year":"2006","journal-title":"Expert. Opin. Pharmacotherapy."},{"key":"10.1016\/j.ejphar.2009.10.024_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00403-006-0707-8","article-title":"The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients","volume":"298","author":"Mrowietz","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejphar.2009.10.024_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.det.2004.03.016","article-title":"Quality-of-life issues in psoriasis","volume":"22","author":"Mukhtar","year":"2004","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.ejphar.2009.10.024_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.024_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-4362.2002.01543.x","article-title":"Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type","volume":"41","author":"Newland","year":"2002","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"Peters","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2009.10.024_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1468-3083.2009.03159.x","article-title":"Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey","volume":"23","author":"Radtke","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.024_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial","volume":"154","author":"Reich","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1185\/030079908X291985","article-title":"Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis","volume":"24","author":"Reich","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2009.10.024_bib35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year","volume":"58","author":"Rich","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1610-0387.2007.06319.x","article-title":"The use of infliximab in dermatology","volume":"5","author":"Rott","year":"2007","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.ejphar.2009.10.024_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.2004.05719.x","article-title":"Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab)","volume":"150","author":"Schmick","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta- analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000090654","article-title":"Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study","volume":"212","author":"Sohn","year":"2006","journal-title":"Dermatology"},{"issue":"Suppl 69","key":"10.1016\/j.ejphar.2009.10.024_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06070.x","article-title":"Biological therapies in the systemic management of psoriasis: International Consensus Conference","volume":"151","author":"Sterry","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2009.10.024_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T20:25:04Z","timestamp":1739391904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299909009157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":41,"alternative-id":["S0014299909009157"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.024","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}